Papadopoulou Anastasia, Alvanou Maria, Karavalakis George, Tzannou Ifigeneia, Yannaki Evangelia
Hematology Department, Hematopoietic Cell Transplantation Unit, Gene and Cell Therapy Center, "George Papanikolaou" Hospital, Thessaloniki, Greece.
University General Hospital of Patras, Greece.
Hemasphere. 2023 Jan 9;7(1):e809. doi: 10.1097/HS9.0000000000000809. eCollection 2023 Jan.
Adoptive immunotherapy with virus-specific cytotoxic T cells (VSTs) has evolved over the last three decades as a strategy to rapidly restore virus-specific immunity to prevent or treat viral diseases after solid organ or allogeneic hematopoietic cell-transplantation (allo-HCT). Since the early proof-of-principle studies demonstrating that seropositive donor-derived T cells, specific for the commonest pathogens post transplantation, namely cytomegalovirus or Epstein-Barr virus (EBV) and generated by time- and labor-intensive protocols, could effectively control viral infections, major breakthroughs have then streamlined the manufacturing process of pathogen-specific T cells (pSTs), broadened the breadth of target recognition to even include novel emerging pathogens and enabled off-the-shelf administration or pathogen-naive donor pST production. We herein review the journey of evolution of adoptive immunotherapy with nonengineered, natural pSTs against infections and virus-associated malignancies in the transplant setting and briefly touch upon recent achievements using pSTs outside this context.
在过去三十年中，采用病毒特异性细胞毒性T细胞（VST）进行过继性免疫疗法已发展成为一种策略，用于在实体器官或异基因造血细胞移植（allo-HCT）后迅速恢复病毒特异性免疫力，以预防或治疗病毒性疾病。自早期原理验证研究表明，针对移植后最常见病原体（即巨细胞病毒或爱泼斯坦-巴尔病毒（EBV））的血清反应阳性供体来源T细胞，通过耗时费力的方案产生，可有效控制病毒感染以来，重大突破随后简化了病原体特异性T细胞（pST）的制造过程，拓宽了目标识别范围，甚至包括新型新兴病原体，并实现了现成可用的给药方式或未接触过病原体的供体pST的生产。我们在此回顾了在移植环境中使用非工程化、天然pST进行过继性免疫疗法针对感染和病毒相关恶性肿瘤的发展历程，并简要提及了在此背景之外使用pST的近期成果。
